跳至主要内容
临床试验/NCT01224769
NCT01224769已完成不适用

A Retrospective Multicenter Trial on Efficacy and Toxicity of Bendamustine Alone or Associated With Rituximab, as Salvage Therapy in Patients With Chronic Lymphoproliferative Disorders

Gruppo Italiano Studio Linfomi1 个研究点 分布在 1 个国家目标入组 109 人开始时间: 2005年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
109
试验地点
1
主要终点
overall response rate

研究概览

简要总结

This retrospective study collects and evaluates the clinical experience reached in Italy on the use of bendamustine alone or combined with rituximab as treatment of patients with relapsed or refractory chronic lymphoproliferative disorders.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients with relapsed or refractory chronic lymphoproliferative disorders
  • salvage treatment with bendamustine +/- rituximab
  • age ≥ 18 years

排除标准

  • previous treatment with bendamustine

研究组 & 干预措施

bendamustine +/- rituximab

干预措施: bendamustine +/- rituximab (Drug)

结局指标

主要结局

overall response rate

时间窗: within 1 month after end of treatment

次要结局

  • prognostic factors(within 1 month after end of treatment)
  • grade III and IV (NCI Common Toxicity Criteria) adverse events(within 1 month after end of treatment)
  • progression free survival(within 1 month after end of treatment)
  • overall survival(within 1 month after end of treatment)

研究者

发起方
Gruppo Italiano Studio Linfomi
申办方类型
Other

研究点 (1)

Loading locations...

相似试验